Search

Displaying results 2071 - 2080 of 10000 in total
  1. Drug

    Cerebrolysin

    go.drugbank.com/drugs/DB16599
    Investigational

    Products: Ambotonin 215,2 mg/ml - parenterale Lösung Injektionslösung/Konzentrat zur Herstellung einer Infusionslösung
  2. Drug

    Besifloxacin

    go.drugbank.com/drugs/DB06771
    Approved

    FDA approved on May 28, 2009.

    Products: BESIVANCE % 0,6 OFTALMIK SÜSPANSIYON, 5 ML
  3. Drug

    Momelotinib

    go.drugbank.com/drugs/DB11763
    ApprovedInvestigational

    Momelotinib works to block the JAK-signal transducer and activator of transcription (STAT) signalling pathway, which is aberrant in MF.[A261561, A261566, A261571] … MF includes primary MF (PMF), post-polycythemia vera (PV) MF, and post-essential thrombocythemia (ET) MF. Clinical manifestations of MF include anemia and thrombocytosis.

    Synonyms: N-(CYANOMETHYL)-4-(2-(4-MORPHOLINOANILINO)PYRIMIDIN-4-YL)BENZAMIDE
  4. Drug

    Tromethamine

    go.drugbank.com/drugs/DB03754
    ApprovedInvestigational

    It is used in the synthesis of surface-active agents and pharmaceuticals; as an emulsifying agent for cosmetic creams and lotions, mineral oil and paraffin wax emulsions, as a biological buffer, and used … (From Merck, 11th ed; Martindale, The Extra Pharmacopoeia, 30th ed, p1424)

    Mixtures: Sooryehan Hyo Fermented Sun BlockCategories: Compounds used in a research, industrial, or household setting
  5. Drug

    Cilgavimab

    go.drugbank.com/drugs/DB16393
    ApprovedInvestigational

    Cilgavimab, in combination with [tixagevimab], was issued an FDA emergency use authorization (EUA) on December 9, 2021, for the pre-exposure prophylaxis of COVID-19 in individuals at increased risk for … [L39411] EVUSHELD was granted marketing authorization by the EMA on March 28, 2022,[L41454] and was approved in Canada soon after, on April 14, 2022.

  6. Drug

    Tixagevimab

    go.drugbank.com/drugs/DB16394
    ApprovedInvestigational

    Tixagevimab, in combination with [cilgavimab], was issued an FDA emergency use authorization (EUA) on December 9, 2021, for the pre-exposure prophylaxis of COVID-19 in individuals at increased risk for … [L39411] EVUSHELD was granted marketing authorization by the EMA on March 28, 2022,[L41454] and was approved in Canada soon after, on April 14, 2022.

  7. Drug

    Meldonium

    go.drugbank.com/drugs/DB13723
    Investigational

    Products: SATURID 100 MG/ ML I.V. ENJEKSIYONLUK ÇÖZELTI IÇEREN AMPUL
  8. Drug

    Quaratusugene ozeplasmid

    go.drugbank.com/drugs/DB19231
    Investigational

    Quaratusugene ozeplasmid is under investigation in clinical trial NCT05062980 (Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-small Lung Cancer).

    Synonyms: Dna-lipid complex (dotap/cholesterol) plasmid vector (plj143/pkgb2/tusc2, baylor) expressing the tusc2 gene
  9. Drug

    Fimasartan

    go.drugbank.com/drugs/DB09279
    Investigational

    Fimasartan was initially approved September 9th, 2010 in South Korea and is marketed under the brand name _Kanarb_ by Boryung Pharmaceuticals. … Fimasartan is an angiotensin II receptor antagonist (ARB) drug employed in the treatment of both hypertension and heart failure.

    Categories: Agents Acting on the Renin-Angiotensin SystemProducts: KANARB®PLUS FILM COATED TABLETS 60 MG/12.5 MG, KANARB®PLUS FILM COATED TABLETS 120 MG/12.5 MG
  10. Drug

    Dermatophagoides pteronyssinus

    go.drugbank.com/drugs/DB10401
    ApprovedInvestigational

    Dermatophagoides pteronyssinus extracts are sterile solutions used for intradermal testing or subcutaneous immunotherapy. This combination is approved for as a year-round, once-a-day tablet that's dissolved under the tongue as a treatmen...

    Mixtures: Allergenic Extract Mixture Of Standardized Mites (5,000 Au/ml), Allergenic Extract Mixture Of Standardized Mites (15,000 Au/ml)Products: Standardized Mite, Dermatophagoides pteronyssinus, Intradermal, 300 AU per mL, Allergenic Extract Standardized Mite Dp (10,000 Au/ml)